Is it possible to end HIV and global health epidemics as public health threats by 2030? The United Nations thinks so, and the guests on this podcast series certainly hope so. But it’s going to take effort, innovation, connections between people and within communities and funding. Welcome to Can We End Epidemics?, a podcast series by the global biopharmaceutical company ViiV Healthcare in association with its biopharma majority shareholder GSK and developed by FP Studios.
All content for Can We End Epidemics? is the property of Foreign Policy and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Is it possible to end HIV and global health epidemics as public health threats by 2030? The United Nations thinks so, and the guests on this podcast series certainly hope so. But it’s going to take effort, innovation, connections between people and within communities and funding. Welcome to Can We End Epidemics?, a podcast series by the global biopharmaceutical company ViiV Healthcare in association with its biopharma majority shareholder GSK and developed by FP Studios.
What does it take to deliver health impact at scale? For the world to reach its ambitious U.N. Sustainable Development Goals, innovation must be accelerated. In this episode, host Henry Bonsu joins Mercy Mwangangi, the director of health systems strengthening at Amref Health Africa, and Fiona Smith-Laittan, the vice president of strategy and operations at GSK’s global health division. They discuss how we can build, strengthen, and future-proof resilient health systems for the 21st century to improve public health and eliminate infectious disease by 2030 and beyond.
Glossary of terms used this season: https://foreignpolicy.com/podcasts/can-we-end-epidemics/
Can We End Epidemics?
Is it possible to end HIV and global health epidemics as public health threats by 2030? The United Nations thinks so, and the guests on this podcast series certainly hope so. But it’s going to take effort, innovation, connections between people and within communities and funding. Welcome to Can We End Epidemics?, a podcast series by the global biopharmaceutical company ViiV Healthcare in association with its biopharma majority shareholder GSK and developed by FP Studios.
